Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IL-24 engineered mesenchymal stem cells
- Development stage
- Preclinical
- Lead developer
- The Chinese University of Hong Kong
- Modality
- Gene Therapies, iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
IL-24 engineered mesenchymal stem cells (IL-24-iMSC) is an experimental cell-based immunotherapy designed to treat non-small cell lung cancer (NSCLC) by remodeling the immunosuppressive tumor microenvironment (TME). The therapy consists of induced mesenchymal stem cells (iMSCs) derived from induced pluripotent stem cells (iPSCs), which are genetically modified using CRISPR/Cas technology to constitutively secrete Interleukin-24 (IL-24). IL-24 is a cytokine known for its pro-inflammatory and anti-tumor properties. By integrating the IL-24 gene into the B2M locus, these cells provide sustained delivery of the cytokine directly into the TME. Preclinical studies indicate that IL-24-iMSCs increase the infiltration of CD8+ T cells and dendritic cells while reducing the presence of regulatory T cells and exhausted T cells, potentially synergizing with immune checkpoint inhibitors.
- Other names
- IL-24-iMSCsIL24-iMSCsIL 24-iMSCsIL-24-expressing induced mesenchymal stem cellsIL24-expressing induced mesenchymal stem cellsIL 24-expressing induced mesenchymal stem cells
02
Targets
IL20RA/IL20RB (Interleukin-20 Receptor)IL-22R1/IL-20R2 (Interleukin-22 receptor subunit alpha-1/Interleukin-20 receptor subunit beta heterodimer)
Beyond the preview
Go deeper on IL-24 engineered mesenchymal stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IL-24 engineered mesenchymal stem cells.